(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 107.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Zevra Therapeutics's revenue in 2025 is $23,612,000.On average, 3 Wall Street analysts forecast ZVRA's revenue for 2025 to be $4,767,770,407, with the lowest ZVRA revenue forecast at $4,647,470,830, and the highest ZVRA revenue forecast at $4,974,871,837. On average, 3 Wall Street analysts forecast ZVRA's revenue for 2026 to be $7,895,667,635, with the lowest ZVRA revenue forecast at $7,484,765,841, and the highest ZVRA revenue forecast at $8,353,325,539.
In 2027, ZVRA is forecast to generate $11,585,125,236 in revenue, with the lowest revenue forecast at $11,301,016,923 and the highest revenue forecast at $11,869,233,548.